Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NILHZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS1TWM2OD1yLkCwOlY6KM7:TR?= Mnq2V2FPT0WU
MV-4-11 NHvNfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\MO5l4UUN3ME2wMlAyPTh4IN88US=> MWHTRW5ITVJ?
NKM-1 NVvueFZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP6fHZKSzVyPUCuNFE3QTlizszN MWrTRW5ITVJ?
ML-2 NFnJfJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P0SmlEPTB;MD6wNVk5OyEQvF2= M2P3N3NCVkeHUh?=
BV-173 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXSTWM2OD1yLkCyN|E1KM7:TR?= NXzxd2FWW0GQR1XS
RS4-11 MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF72fGtKSzVyPUCuNFI2QDdizszN M1TabnNCVkeHUh?=
HL-60 M4jZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMEK5NFgh|ryP NHjqOGNUSU6JRWK=
KY821 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\WdIltUUN3ME2wMlAzQTd3IN88US=> Mn65V2FPT0WU
ECC10 NI\HRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\KPGlEPTB;MD6wN|c6OiEQvF2= NGT2eZNUSU6JRWK=
NCI-H720 MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfkTWM2OD1yLkC0NFEyKM7:TR?= NYrXZWVjW0GQR1XS
QIMR-WIL MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfjToRKSzVyPUCuNFQzQDdizszN NFfJTnpUSU6JRWK=
KG-1 NFzycYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrjOmp6UUN3ME2wMlA1PDh4IN88US=> M4WycHNCVkeHUh?=
TGW MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfOeWFKSzVyPUCuNFQ3OzNizszN M1\rbHNCVkeHUh?=
ATN-1 MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMES3N|Mh|ryP NWfrenpXW0GQR1XS
RH-18 NHLIdGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDtVoNKSzVyPUCuNFYxPDhizszN M3f4eHNCVkeHUh?=
EW-18 M4T5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDzW3FrUUN3ME2wMlA3QDRzIN88US=> MojDV2FPT0WU
NB17 M4j4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPoTWM2OD1yLkC3NVI1KM7:TR?= MVvTRW5ITVJ?
SK-NEP-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwMEeyNVMh|ryP MmHxV2FPT0WU
P12-ICHIKAWA NIrqfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XjWWlEPTB;MD6wO|c4QCEQvF2= NYfSWYtyW0GQR1XS
KARPAS-45 M3LtNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjN[IdKSzVyPUCuNFc5OTVizszN M1LCcXNCVkeHUh?=
EW-3 NUPreFROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEiwOVMh|ryP MmmwV2FPT0WU
NB13 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX3NZdKUUN3ME2wMlA5OjB|IN88US=> NX3zSYxOW0GQR1XS
NCI-H209 MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULGc4FGUUN3ME2wMlA5PzB2IN88US=> NIfRPWdUSU6JRWK=
NCI-H1092 NI\uU|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rt[WlEPTB;MD6xNFI4PSEQvF2= Mn;PV2FPT0WU
NH-12 NYr0fpBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHThO|lKSzVyPUCuNVA4PDRizszN NG\mOWRUSU6JRWK=
697 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIKzWIVKSzVyPUCuNVA5OzlizszN MlPMV2FPT0WU
KE-37 MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LxNWlEPTB;MD6xNVM4KM7:TR?= NHHzT4hUSU6JRWK=
MOLT-4 NY\zWnFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoH0TWM2OD1yLkG1NVY6KM7:TR?= NGm0XXNUSU6JRWK=
CHP-134 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMU[zNFYh|ryP NHLVdYlUSU6JRWK=
D-283MED M2HJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMUe2PFYh|ryP M3L1TXNCVkeHUh?=
LU-135 MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHrOoxtUUN3ME2wMlE5PTV{IN88US=> MVjTRW5ITVJ?
LU-134-A NU\yRYk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDRNWtlUUN3ME2wMlE5PjdzIN88US=> MVvTRW5ITVJ?
EM-2 NFH4O|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDsTWM2OD1yLkG5PVE5KM7:TR?= MlXEV2FPT0WU
LU-139 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMkC0PVgh|ryP NGO1eo9USU6JRWK=
ALL-PO MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETVSoJKSzVyPUCuNlE6QDhizszN NHXPOmJUSU6JRWK=
NB12 MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT5VJl5UUN3ME2wMlI{OTF3IN88US=> NYKweXE{W0GQR1XS
KP-N-YN MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMkO1O|Mh|ryP MVnTRW5ITVJ?
BEN NFL1R4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j3PWlEPTB;MD6yN|k3QCEQvF2= NGDXO2JUSU6JRWK=
HCC1569 NEf2[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMkWxNFYh|ryP M2eyUXNCVkeHUh?=
HuO9 NV\IZ|k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYeweHd6UUN3ME2wMlI3PzF3IN88US=> NUXwUFIxW0GQR1XS
WM-115 MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrMbHNKSzVyPUCuNlc4OzhizszN MlrtV2FPT0WU
CCRF-CEM MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17IZ2lEPTB;MD6zN|UzQSEQvF2= NYe2eJZmW0GQR1XS
IST-SL1 NFvYV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHG0Sm1KSzVyPUCuN|U{PDNizszN NED5ZZNUSU6JRWK=
BE-13 NYr2TpJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwM{[0OVkh|ryP MV\TRW5ITVJ?
COR-L88 Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTkTWM2OD1yLkO2OVQh|ryP M1v2VXNCVkeHUh?=
DOHH-2 MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LoemlEPTB;MD60NVAzOyEQvF2= Mo\GV2FPT0WU
A704 M1XOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rOfmlEPTB;MD60NlY4KM7:TR?= NHzUWZdUSU6JRWK=
KNS-81-FD NFnqcXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjXVIRKSzVyPUCuOFQxOTdizszN M1jMRXNCVkeHUh?=
RPMI-8226 NYG0[YlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrVRVJkUUN3ME2wMlQ2PjV{IN88US=> MWPTRW5ITVJ?
TGBC24TKB MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4O5cGlEPTB;MD60OVc4QCEQvF2= M3Xpc3NCVkeHUh?=
NCI-H1304 NFXRNFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwNE[xOVch|ryP MWDTRW5ITVJ?
MOLT-13 M1rNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTQTWM2OD1yLkS2OlE{KM7:TR?= Moj5V2FPT0WU
EW-22 NGPYXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[wellKSzVyPUCuOFY3PzFizszN Mo[zV2FPT0WU
MS-1 NUHCO4lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHqNm5CUUN3ME2wMlQ3QTN|IN88US=> M1jy[XNCVkeHUh?=
RMG-I NHTJWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPqTWM2OD1yLkS5OFY1KM7:TR?= MYDTRW5ITVJ?
NTERA-S-cl-D1 MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwNUCwNVkh|ryP NVHhUo9iW0GQR1XS
NCI-H1048 Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\oZZhKSzVyPUCuOVA6PTNizszN MXTTRW5ITVJ?
SW1417 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwNUW0N|gh|ryP MljpV2FPT0WU
DB NGPXXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwNUewPEDPxE1? NWHHSHdOW0GQR1XS
MEG-01 NIHkOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjDS2lKSzVyPUCuOVg{OiEQvF2= NIro[5pUSU6JRWK=
EW-13 NYG3fIdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzNUWJuUUN3ME2wMlU5OzRzIN88US=> M3v1OnNCVkeHUh?=
LAMA-84 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn4cZZKSzVyPUCuOVkzODdizszN NWj0SlZVW0GQR1XS
J-RT3-T3-5 M3GxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zyZWlEPTB;MD62NFgxQCEQvF2= NWHhU2xvW0GQR1XS
MOLT-16 NFjy[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVOxXWl{UUN3ME2wMlY2OjZ2IN88US=> M2nPOnNCVkeHUh?=
DU-4475 NH21dmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjqNHBKSzVyPUCuOlU1OjdizszN MljqV2FPT0WU
HAL-01 NWjGfYU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzvbnF5UUN3ME2wMlczPTR7IN88US=> NUDZWmFYW0GQR1XS
RD M1;uRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwN{W4PVkh|ryP MXjTRW5ITVJ?
OAW-28 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwN{izO{DPxE1? MYnTRW5ITVJ?
HCC38 MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPSV3BDUUN3ME2wMlgxOTlizszN NULIUVhTW0GQR1XS
NMC-G1 NGXrTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH5emxpUUN3ME2wMlgyOTJzIN88US=> NGTsflhUSU6JRWK=
EW-16 M3;PNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjXS2lKSzVyPUCuPFE{OjhizszN MWTTRW5ITVJ?
DU-145 MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLrUIFKUUN3ME2wMlg6QTJ|IN88US=> MXLTRW5ITVJ?
HPAF-II M4\SZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\weWlEPTB;MD65NlYzQCEQvF2= MV\TRW5ITVJ?
A427 M1XvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHl[4N{UUN3ME2wMlk{ODJ{IN88US=> MkTNV2FPT0WU
PA-1 Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjHTWM2OD1yLkm1OlQzKM7:TR?= NWf5U2R3W0GQR1XS
OAW-42 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;I[WlKSzVyPUCuPVYyPDZizszN MoLxV2FPT0WU
L-428 NEHQU2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFwMEGyOUDPxE1? NWfzZVdvW0GQR1XS
COLO-824 NWfORlRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v6W2lEPTB;MT6wNVcxQCEQvF2= NGntdppUSU6JRWK=
P30-OHK NUX2SnZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;aNGlEPTB;MT6wOFY5QCEQvF2= M1\BWXNCVkeHUh?=
NCI-H2170 M{jKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFwME[yN{DPxE1? NV3RW4lyW0GQR1XS
HCC2998 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXKxS4EzUUN3ME2xMlA4OTN3IN88US=> M1;WU3NCVkeHUh?=
NB14 NUiwPJp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHIVGdKSzVyPUGuNVM4PDhizszN MkHTV2FPT0WU
TGBC1TKB MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;y[m1zUUN3ME2xMlE1OTV{IN88US=> M1q4V3NCVkeHUh?=
KP-N-YS NYj4d5ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnBTWM2OD1zLkG2NlM3KM7:TR?= MnK3V2FPT0WU
CAL-120 NXfhO291T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3pTWM2OD1zLkG2OFI6KM7:TR?= MUHTRW5ITVJ?
SBC-1 NYXjcJlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD2TWM2OD1zLkG5NFU{KM7:TR?= NF;PNIVUSU6JRWK=
C32 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwMUmwPFgh|ryP NF7sT4ZUSU6JRWK=
HCC2157 MnvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFwMUm0PVQh|ryP NUTVbo5RW0GQR1XS
COLO-792 M3mzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF21eJRKSzVyPUGuNlAxPzFizszN NWnXVFFXW0GQR1XS
ES7 NX\XPWNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkW4TWM2OD1zLkK3PVUyKM7:TR?= NEfCRnZUSU6JRWK=
HEL NWO5WlVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17ZTmlEPTB;MT6zNVAzQSEQvF2= MoLPV2FPT0WU
ES4 M3PJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHuzd|NKSzVyPUGuN|Q6QThizszN MofsV2FPT0WU
NCI-SNU-1 NIfOTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3pTWM2OD1zLkO2OVU2KM7:TR?= M1v2b3NCVkeHUh?=
MDA-MB-415 MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3i[|NKSzVyPUGuN|g5PSEQvF2= M4TnR3NCVkeHUh?=
NCI-H2342 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTrVoZKSzVyPUGuOFAzPjlizszN MkP0V2FPT0WU
NB69 M{HCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrifXhKSzVyPUGuOFYzPzFizszN MYfTRW5ITVJ?
D-247MG NGnRVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\ac4VWUUN3ME2xMlUyOTJ{IN88US=> MX7TRW5ITVJ?
SCC-4 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPWOFRKSzVyPUGuOVk5QDdizszN MkXvV2FPT0WU
HuH-7 NFrNVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITGe4lKSzVyPUGuOlczQTNizszN NHW1bXdUSU6JRWK=
A388 NGH3SGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrxfmJSUUN3ME2xMlY5PzJ2IN88US=> NHW1[oNUSU6JRWK=
Calu-3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTFwN{C2PVch|ryP Mlj5V2FPT0WU
NCI-H1648 M4Wzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TNd2lEPTB;MT63NVQyQCEQvF2= MnPVV2FPT0WU
NCI-H2052 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmntTWM2OD1zLkeyNlAyKM7:TR?= MkOxV2FPT0WU
Ramos-2G6-4C10 NIPiNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK0RZRKSzVyPUGuO|M3PTZizszN M1PxUnNCVkeHUh?=
DEL M3HWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq4TWM2OD1zLke0OlkzKM7:TR?= M1vTOXNCVkeHUh?=
SNU-423 NWLIb445T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPXeHFKSzVyPUGuO|gyPTdizszN NIjPZnZUSU6JRWK=
COR-L23 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP3emNKSzVyPUGuO|k5PzRizszN MWjTRW5ITVJ?
OMC-1 NHPQeVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\mTWM2OD1zLki2NFE3KM7:TR?= M3m4Z3NCVkeHUh?=
EW-11 NILIUYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTPepZHUUN3ME2xMlk2PjV5IN88US=> MnvuV2FPT0WU
HSC-3 Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFwOU[zOlUh|ryP NEntdZJUSU6JRWK=
MLMA NIX5WlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe2NVhKUUN3ME2xMlk3Pjd5IN88US=> NInpPHRUSU6JRWK=
RCM-1 M1LsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33CbGlEPTB;Mj6wNFM6QSEQvF2= MkfQV2FPT0WU
MFE-280 NEK5XWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7rcZZRUUN3ME2yMlAzQDR6IN88US=> NVixdXB5W0GQR1XS
ES8 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm0NnZKSzVyPUKuNlU1PzFizszN NWfZOZVwW0GQR1XS
TE-11 NIHHUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHTTWM2OD1{LkK5OFc{KM7:TR?= M3i5WnNCVkeHUh?=
HuO-3N1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v5eWlEPTB;Mj60PFc5KM7:TR?= MlL3V2FPT0WU
MHH-NB-11 M1fSSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jiWmlEPTB;Mj61NVE2QCEQvF2= MoTPV2FPT0WU
TGBC11TKB M37ISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG2TWM2OD1{LkW3OlgyKM7:TR?= NI\Y[|FUSU6JRWK=
HOP-92 NIrSdGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV31dGNzUUN3ME2yMlU5PzR|IN88US=> NUnxRldYW0GQR1XS
IGR-1 NYC3S2RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJwNkKwN|Uh|ryP NUHYb5FrW0GQR1XS
GOTO MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[0VVVKUUN3ME2yMlY2Ozd5IN88US=> M1v0bHNCVkeHUh?=
NCI-H1650 M{fwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJwN{KyNVUh|ryP NYHrTZc1W0GQR1XS
NCI-H1581 NI\KWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrIRo86UUN3ME2yMlc6PjhzIN88US=> M4K0eXNCVkeHUh?=
NCI-H2405 NFz2eHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O5d2lEPTB;Mj64Nlc5OiEQvF2= M{n0OXNCVkeHUh?=
U-118-MG MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPERlFUUUN3ME2yMlk3PDlzIN88US=> NYHGd|BzW0GQR1XS
DoTc2-4510 M3f3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTNwMEG0NVch|ryP MmK3V2FPT0WU
NCI-H596 NH\aRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjrTWM2OD1|LkC0PVk4KM7:TR?= MX;TRW5ITVJ?
MPP-89 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTNwMEW2OlYh|ryP NUWzPVZHW0GQR1XS
GCIY NVm5TWM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHjTWM2OD1|LkKwOFkyKM7:TR?= M{ixXXNCVkeHUh?=
SW626 Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTNwMkS1OFMh|ryP M1jW[XNCVkeHUh?=
OCI-AML2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvyT2V2UUN3ME2zMlMyOjd{IN88US=> NV[1XnNGW0GQR1XS
NBsusSR M{Pwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[0PJJKSzVyPUOuN|Q6OzhizszN MofiV2FPT0WU
AN3-CA M{HIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HsRWlEPTB;Mz60OFI{QCEQvF2= MlzyV2FPT0WU
EFM-19 Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPEO5ZHUUN3ME2zMlQ5OzN7IN88US=> NV3pVXk6W0GQR1XS
RVH-421 M3jpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm0TWM2OD1|LkW2PFc4KM7:TR?= M1;6eHNCVkeHUh?=
5637 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfI[I1HUUN3ME2zMlYyOTB|IN88US=> M{OxRnNCVkeHUh?=
PANC-08-13 Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHexUJJKSzVyPUOuOlM1PzJizszN M2PhTHNCVkeHUh?=
H9 Mmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTNwNkexOFQh|ryP MX7TRW5ITVJ?
KARPAS-299 NUPr[Hg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2THN2lEPTB;Mz62O|M3OSEQvF2= M3zPfnNCVkeHUh?=
TE-5 NIDKc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVj2cHU3UUN3ME2zMlcxPzB7IN88US=> NG\WRoJUSU6JRWK=
NOS-1 NYC5TXJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTNwN{m4N|Qh|ryP MkHmV2FPT0WU
HH Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\QTWM2OD1|LkizPFY5KM7:TR?= MULTRW5ITVJ?
769-P NWfNe3hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXtTWM2OD1|Lki5OVEh|ryP MVnTRW5ITVJ?
CHP-212 NI\oVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH4RmZZUUN3ME2zMlkzPTR7IN88US=> NFr4eFNUSU6JRWK=
NCI-H82 NEnScGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTmSG5ZUUN3ME2zMlk2QTN4IN88US=> NX;yXXI{W0GQR1XS
Mo-T NGLiXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTRwMESzNVIh|ryP MXHTRW5ITVJ?
BB65-RCC NHWyd41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDKUoRDUUN3ME20MlA1Ozl7IN88US=> NEXlR|hUSU6JRWK=
SW1990 NGDEVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTCb2kxUUN3ME20MlA2QTB6IN88US=> M3PtZ3NCVkeHUh?=
LK-2 MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELlVHpKSzVyPUSuNVEzQTNizszN M1HUUnNCVkeHUh?=
ES5 NFHuPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fsN2lEPTB;ND6xN|k5PSEQvF2= M{XBWHNCVkeHUh?=
JVM-3 NWDhbYp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfITY5KSzVyPUSuNVgzOjJizszN M4nmUXNCVkeHUh?=
RPMI-7951 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHX6XXpKSzVyPUSuNlI1OTNizszN NGjiW|ZUSU6JRWK=
Calu-6 MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf2OmZKSzVyPUSuNlc5QDFizszN NFXBSXJUSU6JRWK=
LC-2-ad NF7nNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvPfYxRUUN3ME20MlI6PTZ6IN88US=> M3HW[XNCVkeHUh?=
SW954 MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHhTWM2OD12LkK5OlYh|ryP MWfTRW5ITVJ?
H-EMC-SS M4i0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTRwM{G4N|Eh|ryP MWHTRW5ITVJ?
ES3 M3zuemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX3TWM2OD12LkO1OFQyKM7:TR?= NHfyUolUSU6JRWK=
no-11 M2nWPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTRwM{W1OVQh|ryP M3vxO3NCVkeHUh?=
LAN-6 NH3BemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTRwNEWxPFkh|ryP M4LEOnNCVkeHUh?=
FTC-133 M2HKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnzTWM2OD12LkWzPVUh|ryP MoLvV2FPT0WU
8505C MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjIXWU2UUN3ME20MlU1OjNizszN NF[5RWxUSU6JRWK=
SW620 M1LD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvJTWM2OD12LkW3NFU4KM7:TR?= NV\xbGdkW0GQR1XS
BCPAP NITo[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLQbY1KSzVyPUSuOlM1QDFizszN MlLhV2FPT0WU
SK-LU-1 NVTtRmx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorVTWM2OD12Lk[2NFg6KM7:TR?= M4XzXnNCVkeHUh?=
NCI-H1623 MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkn2TWM2OD12LkewNlI5KM7:TR?= NYX3[5BIW0GQR1XS
C2BBe1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknaTWM2OD12Lke0NFA5KM7:TR?= M3nVTHNCVkeHUh?=
GP5d M{\Vbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInTb5ZKSzVyPUSuO|g{QDhizszN NHXBUZlUSU6JRWK=
NB6 M3POb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XudGlEPTB;ND64OlIxPCEQvF2= MkTKV2FPT0WU
MDA-MB-157 NE\yNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDzNIt5UUN3ME20Mlg5PzZizszN MmqyV2FPT0WU
UMC-11 M2XtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTRwOEi5OlQh|ryP Mmj1V2FPT0WU
HCC1419 NHX4VJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTRwOUCwOlMh|ryP NWHOeZFsW0GQR1XS
NCI-H2029 NVzJcIh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljDTWM2OD12Lkm0NVg2KM7:TR?= M13FU3NCVkeHUh?=
LXF-289 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zoTmlEPTB;NT6wN|cyQSEQvF2= NWDHWXpXW0GQR1XS
KINGS-1 M3q4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTVwMEe3OFQh|ryP M1[3W3NCVkeHUh?=
HD-MY-Z NX7INpY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\pcpIxUUN3ME21MlI{QTZ7IN88US=> NV;DPGNxW0GQR1XS
ESS-1 NEj3S|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXuTWM2OD13LkK1OVk4KM7:TR?= MYLTRW5ITVJ?
GI-1 NGPzO|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XOW2lEPTB;NT6yO|kzPiEQvF2= MlHxV2FPT0WU
RPMI-2650 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTVwM{[xOkDPxE1? M3;IfnNCVkeHUh?=
IA-LM M4rSNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;COFN{UUN3ME21MlM6QDdzIN88US=> MlLvV2FPT0WU
KP-4 Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHiWXBSUUN3ME21MlQ3OzN2IN88US=> M2HISHNCVkeHUh?=
G-402 Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjZTWM2OD13LkWxPFY2KM7:TR?= NGnq[GpUSU6JRWK=
OS-RC-2 MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfmboVKSzVyPUWuOVI3ODRizszN NFS4[45USU6JRWK=
NCI-H1155 MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTWTWM2OD13LkW0PVU2KM7:TR?= MnHwV2FPT0WU
OE19 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETpZmhKSzVyPUWuOlg3OjRizszN NYnGN|NjW0GQR1XS
U-2-OS NFP2fHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTVwOEmwNVMh|ryP MmnuV2FPT0WU
SCC-15 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrUc49KSzVyPUWuPVM3PjJizszN MX7TRW5ITVJ?
NCI-H630 NWTsV2ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTVwOUm0NFQh|ryP NF;aPGlUSU6JRWK=
PFSK-1 NH\VTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzZToROUUN3ME22MlA2OjV7IN88US=> NH;1[ohUSU6JRWK=
NCI-H1770 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTZwMkC4O|Qh|ryP NUjHU|I1W0GQR1XS
SK-MEL-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7JUo9KSzVyPU[uOFI6OTVizszN NEX3OopUSU6JRWK=
LB1047-RCC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fOZWlEPTB;Nj60O|YzPSEQvF2= MlvqV2FPT0WU
NCI-H446 NU\mZZZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFruOGRKSzVyPU[uOlI6OjVizszN NUHGRlYyW0GQR1XS
SW780 NHzK[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTZwN{CxPFUh|ryP NEnyVZVUSU6JRWK=
NEC8 NEjm[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PCW2lEPTB;Nj63OlY{KM7:TR?= M2P2THNCVkeHUh?=
NOMO-1 NWrUdVlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jKW2lEPTB;Nj63PFEyOSEQvF2= NYfMd5g{W0GQR1XS
COLO-668 MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu0cG1KSzVyPU[uPFQ{QDdizszN MWPTRW5ITVJ?
MC116 NFntTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\pXmlEPTB;Nj65N|g6PyEQvF2= MoH2V2FPT0WU
HCC1937 NHLUcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfWUoN7UUN3ME22Mlk6OjVzIN88US=> M37GRnNCVkeHUh?=
NCI-N87 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3aWHNKSzVyPUeuNVkzQTNizszN MV7TRW5ITVJ?
COLO-320-HSR NYrCSXJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PGXGlEPTB;Nz6yNlc{QCEQvF2= NFrBUWtUSU6JRWK=
HCC1806 NWnDZng{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\EPXhnUUN3ME23MlI3ODR2IN88US=> M{\LbHNCVkeHUh?=
OVCAR-3 Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTdwM{OwN|gh|ryP M2TzXHNCVkeHUh?=
NUGC-3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXixc4l3UUN3ME23MlM6Pjl2IN88US=> NVPiR2E4W0GQR1XS
SW1783 MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTdwNEOxO|Uh|ryP NHzGOGpUSU6JRWK=
GCT MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULsd4hQUUN3ME23MlU3QTB4IN88US=> Mmj0V2FPT0WU
NCI-H2126 M17zWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjGUZlHUUN3ME23Mlc{PjJ3IN88US=> M4npVXNCVkeHUh?=
MEL-HO NH3CRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLmOYJuUUN3ME23Mlc4ODV2IN88US=> M{C5fHNCVkeHUh?=
CAPAN-1 MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTdwN{ezOVch|ryP NXXlR4VIW0GQR1XS
SW756 NGXzTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTdwN{izN|Mh|ryP NYD2Z|RbW0GQR1XS
SKG-IIIa MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPtS|lKSzVyPUeuPFE5QTJizszN Mlm4V2FPT0WU
HCE-T NWTxb254T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTdwOEe3PFMh|ryP MXjTRW5ITVJ?
Ca-Ski Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkiyTWM2OD15Lkm5N|g{KM7:TR?= MnfTV2FPT0WU
COLO-684 MkDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEC5bIRKSzVyPUiuNFE5OThizszN MXHTRW5ITVJ?
KYSE-70 NIXscnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jq[GlEPTB;OD6wO|czQSEQvF2= MXnTRW5ITVJ?
TI-73 M4XaNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRThwMkW4OVEh|ryP MnmxV2FPT0WU
BT-20 NVPWSnFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fhXGlEPTB;OD6yOlA2OiEQvF2= NYTXdJltW0GQR1XS
MHH-ES-1 MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXubnpKSzVyPUiuOVE5OzRizszN MXXTRW5ITVJ?
TE-12 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRThwNUm5N|Eh|ryP NIX6cIFUSU6JRWK=
YH-13 M{mxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRThwNkGwNFgh|ryP NV;MTWJMW0GQR1XS
SF126 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XxZmlEPTB;OD64N|g3PSEQvF2= M1PTO3NCVkeHUh?=
J82 MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW3TWM2OD16LkmwNFM5KM7:TR?= NGW4bo5USU6JRWK=
RCC10RGB MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHCXpFDUUN3ME24Mlk6PTZzIN88US=> MXzTRW5ITVJ?
SK-UT-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXQO5dKSzVyPUmuNFQ6PDVizszN MUPTRW5ITVJ?
LB2241-RCC NX\uZW1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjL[|N5UUN3ME25MlE6OTN5IN88US=> NV\EeWhCW0GQR1XS
LB996-RCC NH\5THlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTlwMUm4PUDPxE1? NWDhZ3l7W0GQR1XS
EPLC-272H M4HhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTlwM{e2OVch|ryP NUX1dFY{W0GQR1XS
CTV-1 M4S5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PSWWlEPTB;OT61OlU{OiEQvF2= MXjTRW5ITVJ?
HSC-2 NUO1bZhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTlwNUe1OUDPxE1? NXzjellCW0GQR1XS
SK-MEL-28 M4[1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV24[WdSUUN3ME25MlYyQDl|IN88US=> NFWzS3ZUSU6JRWK=
MMAC-SF MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf6VmpKSzVyPUmuOlg4PSEQvF2= NFPPdGZUSU6JRWK=
CP50-MEL-B NXezVFR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjaT|d2UUN3ME25Mlc2Pzh{IN88US=> NHnnT4JUSU6JRWK=
HT-1080 NHPEfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTlwN{e3N|kh|ryP NHj6e2FUSU6JRWK=
HEC-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoS4TWM2OD1zMD6zN|UzKM7:TR?= NV36WmxIW0GQR1XS
AGS MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\zcmlEPTB;MUCuN|c1KM7:TR?= MkOxV2FPT0WU
GAMG NV7KcFhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XQW2lEPTB;MUCuOVE3OiEQvF2= NID6XpJUSU6JRWK=
SW48 NWW0[4xVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LJNGlEPTB;MUCuOVE5QSEQvF2= MWHTRW5ITVJ?
U031 NWe3RpZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG2PFZKSzVyPUGwMlU6ODhizszN NWLW[IsyW0GQR1XS
OVCAR-5 NXX0PZltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvGTWM2OD1zMD62OFI6KM7:TR?= NVqxXlNwW0GQR1XS
SF295 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly5TWM2OD1zMD62O|A1KM7:TR?= MlmyV2FPT0WU
BHT-101 Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrnOotSUUN3ME2xNE44OTd5IN88US=> M3nSZ3NCVkeHUh?=
VMRC-RCZ M{fiR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnHRVFKSzVyPUGxMlMzODFizszN M4HaWXNCVkeHUh?=
ACHN NFrEV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q4eGlEPTB;MUGuOFIyOSEQvF2= M{TCO3NCVkeHUh?=
NCI-H526 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFzLkWwOFMh|ryP NW\zUZRPW0GQR1XS
MN-60 M3TKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;KTWM2OD1zMT61N|kh|ryP NHvhblNUSU6JRWK=
NCI-H2291 MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rneGlEPTB;MUGuOVQ3PiEQvF2= MWrTRW5ITVJ?
SCC-25 NVr1RnBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnSc2RoUUN3ME2xNU44PTV4IN88US=> M{GxNXNCVkeHUh?=
SK-MEL-2 NIniNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzITWM2OD1zMT63OlM4KM7:TR?= Mkn4V2FPT0WU
SN12C NFf3XGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFzLkmzOVUh|ryP NWTnPFhoW0GQR1XS
NCI-H69 NVHDTXB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jiZWlEPTB;MUKuOFI{PCEQvF2= M3jH[HNCVkeHUh?=
ME-180 M{DPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfCb2dNUUN3ME2xNk44ODV2IN88US=> NF;0SYtUSU6JRWK=
MC-IXC NUXISFZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXmTI5WUUN3ME2xNk44PTF6IN88US=> NIHGWFZUSU6JRWK=
NCI-H2347 MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjMT4pKSzVyPUGyMlc3OTRizszN MnjLV2FPT0WU
M059J MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTzTWM2OD1zMj63O|I4KM7:TR?= MUTTRW5ITVJ?
A2058 NUjGOJdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PObGlEPTB;MUKuPFY5OSEQvF2= NEHJW5VUSU6JRWK=
VA-ES-BJ NVnHXlJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe5ZmV3UUN3ME2xNk45Pzh3IN88US=> M2rTdHNCVkeHUh?=
Ca9-22 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz1PW1rUUN3ME2xNk46PDVzIN88US=> M3rr[3NCVkeHUh?=
KNS-42 M1zZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjOTWM2OD1zMj65PVg1KM7:TR?= MkH5V2FPT0WU
LoVo MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXhTWM2OD1zMz6yN|E{KM7:TR?= M4fpSXNCVkeHUh?=
AM-38 NHrFeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF|LkK1OlYh|ryP MUXTRW5ITVJ?
NB5 MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF|LkO3OVIh|ryP M4jTSnNCVkeHUh?=
L-363 Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;MUWlEPTB;MUOuOFA{OyEQvF2= M3zjV3NCVkeHUh?=
SK-MEL-30 M{nHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrVeIwyUUN3ME2xOE4xPjR3IN88US=> NXToT2N[W0GQR1XS
NCI-H1563 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHvc5N4UUN3ME2xOE43ODN7IN88US=> M2LTbHNCVkeHUh?=
NCI-H2228 NH3qbppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXWfZBKSzVyPUG0MlYxPzdizszN M{\hXHNCVkeHUh?=
MFM-223 NIjoNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF3LkG4NVMh|ryP MoLqV2FPT0WU
LB831-BLC MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHq2eJRKSzVyPUG1MlI4PjdizszN MYnTRW5ITVJ?
SW872 MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF3LkOwPFYh|ryP MlLvV2FPT0WU
NCI-H522 MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jueGlEPTB;MUWuN|MxPiEQvF2= NHXmdotUSU6JRWK=
EW-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELxO4ZKSzVyPUG1MlU1PjJizszN MkTYV2FPT0WU
HN NEfKcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF3LkW5OFIh|ryP MVHTRW5ITVJ?
SW837 NWTBVXJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXBPWN6UUN3ME2xOU44QDR5IN88US=> M3yzb3NCVkeHUh?=
SCC-9 MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvNTWM2OD1zNT64NVE1KM7:TR?= MWDTRW5ITVJ?
MKN7 MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnyTWM2OD1zNT65O|MzKM7:TR?= M3vmWnNCVkeHUh?=
KYSE-410 MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\zVmlEPTB;MU[uOVkyKM7:TR?= MnnDV2FPT0WU
SK-N-DZ MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjxe2p6UUN3ME2xOk43OTF4IN88US=> NIrpdlNUSU6JRWK=
COR-L105 NUCwU21qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF4Lk[1Nlgh|ryP MlXjV2FPT0WU
LB2518-MEL M37LV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF4LkizPFkh|ryP MXrTRW5ITVJ?
OVCAR-4 NFzOXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPETWM2OD1zNj64PFYzKM7:TR?= M4rOdXNCVkeHUh?=
TK10 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrSTJFKSzVyPUG2Mlk1PzNizszN NF3UR2NUSU6JRWK=
KNS-62 NXK1T2hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;FTIR2UUN3ME2xOk46Pzd5IN88US=> M1ra[XNCVkeHUh?=
RPMI-8866 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7yTWM2OD1zNz6xO|MzKM7:TR?= M4DlUXNCVkeHUh?=
HuP-T4 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;pS2NpUUN3ME2xO{4zPDl3IN88US=> NUPNO3JiW0GQR1XS
CGTH-W-1 NXfhcVc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjtTWM2OD1zNz61NlE6KM7:TR?= MnjhV2FPT0WU
T-24 NVjEbXNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjqRpBKSzVyPUG3MlU{PDdizszN M1TaZnNCVkeHUh?=
HT-3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\nN3VVUUN3ME2xO{42QTF2IN88US=> MnPVV2FPT0WU
KS-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\RWIx3UUN3ME2xO{43PzNizszN NGTvUlJUSU6JRWK=
NCI-H1792 NFPsdVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y3SGlEPTB;MUeuO|k5KM7:TR?= NEXK[XFUSU6JRWK=
ABC-1 NVHxS2hWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrxTWM2OD1zNz64NVQyKM7:TR?= NV\O[JBQW0GQR1XS
BPH-1 M4TGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYniOJhWUUN3ME2xPE4yPjh3IN88US=> NEO4cFFUSU6JRWK=
A431 MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLtTWM2OD1zOD60NVI4KM7:TR?= NXfw[4FyW0GQR1XS
T98G M4Oyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XvN2lEPTB;MUiuOVE2PyEQvF2= MULTRW5ITVJ?
BHY MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvFSYNsUUN3ME2xPE45PjlizszN NH2xXZdUSU6JRWK=
Capan-2 NGD3XYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF6LkmwO|gh|ryP Mlj4V2FPT0WU
MDA-MB-175-VII NXPJUpVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTF6LkmyNFkh|ryP NXLkXGp1W0GQR1XS
CAL-27 NWH4e5pnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXSzWndIUUN3ME2xPU4xPDh5IN88US=> NVL5flBiW0GQR1XS
AsPC-1 MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjES2tKSzVyPUG5Mlg3PTdizszN NG\0e2dUSU6JRWK=
KU812 NED2[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\RNFBKSzVyPUG5Mlk2PzNizszN NU\1eIhTW0GQR1XS
NCI-H441 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJyLkCwNUDPxE1? NHe0eGdUSU6JRWK=
Mewo MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz4RmFbUUN3ME2yNE4yOjh6IN88US=> Mn25V2FPT0WU
SK-MEL-24 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fWbGlEPTB;MkCuNVQ4PyEQvF2= MWnTRW5ITVJ?
NCI-H727 MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vxOmlEPTB;MkCuNlcxPCEQvF2= NV\tXZdSW0GQR1XS
EKVX MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDYTGRKSzVyPUKwMlYxPiEQvF2= NEjlPGFUSU6JRWK=
RT-112 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYOxdWVqUUN3ME2yNE43OTJ{IN88US=> MlXTV2FPT0WU
CAMA-1 NXGzemJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVuyWINIUUN3ME2yNE46QDB|IN88US=> MV;TRW5ITVJ?
SW900 NHL5eo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJzLkCxOFkh|ryP NFS2dmFUSU6JRWK=
NCI-H23 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDxN|dKSzVyPUKxMlEzPzdizszN MoPDV2FPT0WU
SK-PN-DW NIjaVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH6bGU4UUN3ME2yNU4yPjR7IN88US=> NUOwe3U1W0GQR1XS
BB30-HNC M3XqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnwXGtYUUN3ME2yNU4zPzR3IN88US=> NFP0Zm1USU6JRWK=
VM-CUB-1 MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJzLkO1N|Yh|ryP NIjubGxUSU6JRWK=
IST-MEL1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fiOGlEPTB;MkGuN|Y6OiEQvF2= NELkb4xUSU6JRWK=
CTB-1 MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJzLkS3OVUh|ryP MVvTRW5ITVJ?
LCLC-103H NWXWRlNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4WwVGlEPTB;MkKuNVU5OiEQvF2= NF;IWFRUSU6JRWK=
PANC-03-27 NXr4RWJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO4SVN7UUN3ME2yNk42OTZ7IN88US=> NEn2UnpUSU6JRWK=
HTC-C3 NX\GPXdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTTRm5RUUN3ME2yNk42PTV3IN88US=> M1TLVHNCVkeHUh?=
TE-8 NWHOXIUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D4TGlEPTB;MkOuNlU3PSEQvF2= NXTQRnVnW0GQR1XS
NCI-H292 NYTa[4p7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml65TWM2OD1{NT6zOVM3KM7:TR?= MmHpV2FPT0WU
COLO-680N Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHyT5pKSzVyPUK1MlY{OjlizszN MVjTRW5ITVJ?
KYSE-520 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJ3Lk[0OEDPxE1? NFLEfZhUSU6JRWK=
NB10 NGfBdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJ4LkOxNVch|ryP MojYV2FPT0WU
NCI-H661 M{\W[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\0OYpKSzVyPUK2MlQ4OTNizszN NEiyWlVUSU6JRWK=
GMS-10 NGPaV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmf3TWM2OD1{Nj64OlM5KM7:TR?= NFPlPHVUSU6JRWK=
NCI-H2122 M3q3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJ4Lkm5PVgh|ryP MYrTRW5ITVJ?
OVCAR-8 Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3GTWM2OD1{Nz6wOlM5KM7:TR?= M3HV[3NCVkeHUh?=
DJM-1 NVLX[m57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknDTWM2OD1{Nz6xOFU1KM7:TR?= MmjwV2FPT0WU
UACC-893 NYnEcFVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDLd4hKSzVyPUK3Mlk5PzhizszN M3jlbnNCVkeHUh?=
C8166 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJ6Lk[5N|gh|ryP Ml;2V2FPT0WU
NCI-H1693 MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHTdo5WUUN3ME2yPE43QTd3IN88US=> MV7TRW5ITVJ?
TYK-nu MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3Nc2MxUUN3ME2zNE4xOzR3IN88US=> NGHIS49USU6JRWK=
SW1710 NVXCXpg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTNyLkGyOkDPxE1? NXXwbVdQW0GQR1XS
A375 Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrvPJFKSzVyPUOwMlMzPDNizszN Mme3V2FPT0WU
HMV-II NHvYOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK0[JhKSzVyPUOxMlM2QTJizszN MkXjV2FPT0WU
NCI-H2087 NGjOeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILPOG9KSzVyPUOxMlY{PTJizszN NGPjWGVUSU6JRWK=
CAL-54 NGjXR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjOXo9KSzVyPUOxMlczPDFizszN MnfTV2FPT0WU
HCC70 NXfyW|V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTN{LkGzPFch|ryP MVrTRW5ITVJ?
ES1 M4L2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HS[GlEPTB;M{KuN|A3OiEQvF2= NWD2VVFQW0GQR1XS
NCI-H1355 NFKzcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm5c2lKSzVyPUOzMlIxPCEQvF2= MXzTRW5ITVJ?
CFPAC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7pbW5xUUN3ME2zN{4zOzN{IN88US=> NV;1RYE4W0GQR1XS
MKN28 M{exR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3xepZDUUN3ME2zN{4{QDB7IN88US=> NEPHN4hUSU6JRWK=
HDLM-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\Lc2ZzUUN3ME2zN{43QTNzIN88US=> NXziW3M{W0GQR1XS
PANC-10-05 M{PvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLMVIJKSzVyPUO0MlExOTRizszN MYPTRW5ITVJ?
SAS MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnrbnBKSzVyPUO0MlQ2PjVizszN MUnTRW5ITVJ?
HCC1395 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3PT25KSzVyPUO0MlcyQDZizszN MV7TRW5ITVJ?
8305C NX3VTVZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHlZYh4UUN3ME2zOU45PDF3IN88US=> NH;MT2NUSU6JRWK=
KM12 NGLONWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDCZo5KSzVyPUO2Mlc2PDdizszN MXfTRW5ITVJ?
SW1116 M4[5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorPTWM2OD1|Nz61PVkzKM7:TR?= MYDTRW5ITVJ?
SK-MEL-1 NY\tOHF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfNblBUUUN3ME2zPE4{Ozh7IN88US=> MVvTRW5ITVJ?
HCC2218 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfw[oxKSzVyPUO4MlY2OTlizszN NXy3SVBtW0GQR1XS
T84 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XCUmlEPTB;M{iuO|QxQSEQvF2= MVHTRW5ITVJ?
ETK-1 Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PUTmlEPTB;M{muNFIzKM7:TR?= NWX5bFVnW0GQR1XS
COLO-800 M1;hPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPVO|F4UUN3ME2zPU4{QDZ6IN88US=> NGXDR3dUSU6JRWK=
CAL-12T NULieYtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrocoFKSzVyPUO5MlUzQDFizszN NXXIbIxsW0GQR1XS
ACN MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TORWlEPTB;NECuOFkyOSEQvF2= MX;TRW5ITVJ?
SJSA-1 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTRzLkG1PVYh|ryP MnK1V2FPT0WU
PSN1 Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXKbJlFUUN3ME20NU4yPzR7IN88US=> MVjTRW5ITVJ?
D-566MG NYjZcJB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLtTWM2OD12MT6yNFg3KM7:TR?= NV3vXnZQW0GQR1XS
EGI-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTR{LkSyPEDPxE1? MnHxV2FPT0WU
A204 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTVTWM2OD12Mj62N|g5KM7:TR?= M3LMeXNCVkeHUh?=
Saos-2 NUWzbnh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jNPGlEPTB;NEKuPFM3QSEQvF2= NXPZXXRNW0GQR1XS
SNU-C2B MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH0PFVKSzVyPUSzMlY5PzhizszN NFzibZhUSU6JRWK=
HLE MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTR2LkC4OVYh|ryP MV\TRW5ITVJ?
SW1463 NFv0[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTR2Lkm5O|Eh|ryP MnvEV2FPT0WU
DSH1 M2DlNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPJTWM2OD12NT6wNFM{KM7:TR?= M3vZZXNCVkeHUh?=
MCF7 Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTR3LkWwOVEh|ryP MUPTRW5ITVJ?
K5 NWHXPW1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HTfGlEPTB;NEWuPVQxPSEQvF2= NUnZOXdoW0GQR1XS
NCI-H358 NWTpdXM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITIcY9KSzVyPUS3MlIyPSEQvF2= MUXTRW5ITVJ?
NCI-H2030 Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT0TWM2OD12Nz6yN|c1KM7:TR?= MWjTRW5ITVJ?
SW948 MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DF[mlEPTB;NEeuOFY1KM7:TR?= M1HoVHNCVkeHUh?=
BALL-1 NXzpUGpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHITnFNUUN3ME20O{43OTZ6IN88US=> NGfsW3FUSU6JRWK=
TE-9 NET1fYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH2wfXhKSzVyPUS3Mlk2QDFizszN NYLJTHlrW0GQR1XS
SK-N-FI MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXtemZRUUN3ME20PE4xOzV6IN88US=> M1n1d3NCVkeHUh?=
KALS-1 NY\YOopDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;STWM2OD12OD6xNlg6KM7:TR?= MXHTRW5ITVJ?
HO-1-N-1 NWG2clZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYToSnlxUUN3ME20PE44PDR3IN88US=> NYTkdlJOW0GQR1XS
NCI-H2452 NHHqOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTR7LkGxOVIh|ryP MW\TRW5ITVJ?
OC-314 NXvne29WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jlc2lEPTB;NEmuOlg{PCEQvF2= NVvZPZBjW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02143401 Recruiting Cirrhosis|Hepatitis B Infection|Hepatitis C Infection|Metastatic Malignant Solid Neoplasm|Recurrent Hepatocellular Carcinoma|Recurrent Malignant Solid Neoplasm|Refractory Malignant Neoplasm|Stage IV Hepatocellular Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 7 2014 Phase 1
NCT02079740 Recruiting Advanced Malignant Solid Neoplasm|KRAS Gene Mutation|Metastatic Malignant Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7|Unresectable Malignant Neoplasm National Cancer Institute (NCI) March 7 2014 Phase 1|Phase 2
NCT03222609 Recruiting Myelofibrosis (MF) AbbVie October 31 2017 Phase 2
NCT02520778 Recruiting EGFR Activating Mutation|EGFR Exon 19 Deletion Mutation|EGFR NP_005219.2:p.G719X|EGFR NP_005219.2:p.L858R|EGFR NP_005219.2:p.L861Q|EGFR NP_005219.2:p.T790M|Stage III Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Non-Small Cell Lung Cancer AJCC v7|Stage IV Non-Small Cell Lung Cancer AJCC v7 National Cancer Institute (NCI) March 31 2016 Phase 1
NCT03366103 Recruiting Metastatic Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Small Cell Lung Carcinoma|Stage III Small Cell Lung Carcinoma AJCC v7|Stage IIIA Small Cell Lung Carcinoma AJCC v7|Stage IIIB Small Cell Lung Carcinoma AJCC v7|Stage IV Small Cell Lung Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 29 2017 Phase 1|Phase 2
NCT03181126 Recruiting Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 28 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID